Compare · ESLA vs RVMD
ESLA vs RVMD
Side-by-side comparison of Estrella Immunopharma Inc. (ESLA) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ESLA and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $34.65B, about 847.6x ESLA ($40.9M).
- Over the past year, ESLA is up 16.4% and RVMD is up 310.5% - RVMD leads by 294.0 points.
- RVMD has been more active in the news (13 items in the past 4 weeks vs 1 for ESLA).
- RVMD has more recent analyst coverage (25 ratings vs 0 for ESLA).
- Company
- Estrella Immunopharma Inc.
- Revolution Medicines Inc.
- Price
- $1.11+3.74%
- $162.84+3.15%
- Market cap
- $40.9M
- $34.65B
- 1M return
- -11.90%
- +10.42%
- 1Y return
- +16.45%
- +310.49%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2020
- News (4w)
- 1
- 13
- Recent ratings
- 0
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest ESLA
- SEC Form DEF 14A filed by Estrella Immunopharma Inc.
- SEC Form 10-Q filed by Estrella Immunopharma Inc.
- SEC Form NT 10-Q filed by Estrella Immunopharma Inc.
- SEC Form SCHEDULE 13G filed by Estrella Immunopharma Inc.
- Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
- Amendment: SEC Form 10-K/A filed by Estrella Immunopharma Inc.
- Chief Financial Officer Xu Jiandong bought $2,594 worth of shares (2,100 units at $1.24), increasing direct ownership by 0.38% to 265,488 units (SEC Form 4)
- Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
- SEC Form 424B3 filed by Estrella Immunopharma Inc.
- Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
Latest RVMD
- Officer Mancini Anthony sold $720,490 worth of shares (4,615 units at $156.12), decreasing direct ownership by 8% to 49,975 units (SEC Form 4) to satisfy withholding tax
- Officer Goldsmith Mark A sold $1,564,310 worth of shares (10,020 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 267,330 units (SEC Form 4) to satisfy withholding tax
- General Counsel Cislini Jeff sold $336,749 worth of shares (2,157 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 56,521 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Anders Jack sold $424,956 worth of shares (2,722 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,269 units (SEC Form 4) to satisfy withholding tax
- Officer Kelsey Stephen Michael sold $651,798 worth of shares (4,175 units at $156.12) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 291,876 units (SEC Form 4) (withholding tax)
- Chief Operating Officer Horn Margaret A exercised 90,000 shares at a strike of $30.82 and sold $14,972,110 worth of shares (93,575 units at $160.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 154,647 units (SEC Form 4) to cover taxes
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.